Andrew Hill Investment Advisors Inc. Invests $338,000 in Stryker Corporation $SYK

Andrew Hill Investment Advisors Inc. purchased a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, Holdings Channel.com reports. The fund purchased 854 shares of the medical technology company’s stock, valued at approximately $338,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Capital A Wealth Management LLC purchased a new stake in shares of Stryker during the 4th quarter worth approximately $26,000. Goodman Advisory Group LLC acquired a new position in Stryker during the first quarter worth $32,000. City Holding Co. boosted its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares in the last quarter. Ransom Advisory Ltd acquired a new stake in Stryker in the first quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker during the 1st quarter worth $40,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Stryker stock opened at $376.60 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The stock’s 50 day moving average price is $388.10 and its 200 day moving average price is $379.40. The firm has a market capitalization of $143.98 billion, a PE ratio of 49.88, a price-to-earnings-growth ratio of 2.71 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SYK. Citigroup reaffirmed a “buy” rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Truist Financial set a $415.00 price target on Stryker and gave the stock a “hold” rating in a report on Monday, August 4th. Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Friday, July 18th. Finally, Evercore ISI lifted their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $431.42.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.